Literature DB >> 8563497

Chemokines as mediators of allergic inflammation.

K B Bacon1, T J Schall.   

Abstract

The selective distribution of reactive leukocytes to foci of inflammation or lymphoid organs is thought to rely on the generation of highly specific 'attractive' forces which can enhance or subvert the physiological trafficking process. It is becoming increasingly apparent that the selective trafficking of leukocytes is governed by both the release of soluble mediators, or chemoattractants, as well as the matrix upon or through which the cells must traverse. A balance exists between endogenous cellular adhesion receptors (as well as extracellular matrix proteins) and other inducible adhesion receptors which can be up-regulated on this 'docking station'. This dynamic environment provides a prominent signal for leukocyte extravasation from the blood or lymph vessel lumenal surface through to the tissue space. This report reviews current thinking on the delicate interplay between a superfamily of chemoattractant cytokines, the chemokines, and the various classes of cellular adhesion molecules. In it we highlight the idea that the balance between basal and inducible regulators of cell adhesion and migration is critical. Should it be disrupted, the signals responsible for induction and maintenance of an inflammatory response and those responsible for its resolution become disregulated, resulting in inflammatory pathology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8563497     DOI: 10.1159/000237207

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  9 in total

1.  TAK1 regulates NF-ΚB and AP-1 activation in airway epithelial cells following RSV infection.

Authors:  Nilay Dey; Tianshuang Liu; Roberto P Garofalo; Antonella Casola
Journal:  Virology       Date:  2011-08-10       Impact factor: 3.616

2.  Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin.

Authors:  M M Teixeira; T N Wells; N W Lukacs; A E Proudfoot; S L Kunkel; T J Williams; P G Hellewell
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  Dominant role of L- and P-selectin in mediating CXC chemokine-induced neutrophil migration in vivo.

Authors:  J M Miotla; V C Ridger; P G Hellewell
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

4.  Respiratory syncytial virus infection induces the release of transglutaminase 2 from human airway epithelial cells.

Authors:  Kempaiah Rayavara; Alexander Kurosky; Yashoda M Hosakote
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-10-27       Impact factor: 5.464

5.  Proinflammatory Effects of Respiratory Syncytial Virus-Induced Epithelial HMGB1 on Human Innate Immune Cell Activation.

Authors:  Kempaiah Rayavara; Alexander Kurosky; Susan J Stafford; Nisha J Garg; Allan R Brasier; Roberto P Garofalo; Yashoda M Hosakote
Journal:  J Immunol       Date:  2018-10-01       Impact factor: 5.422

6.  The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity In vivo.

Authors:  S Mahalingam; J M Farber; G Karupiah
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

7.  Lymphotactin: a key regulator of lymphocyte trafficking during acute graft rejection.

Authors:  J D Wang; N Nonomura; S Takahara; B S Li; H Azuma; N Ichimaru; Y Kokado; K Matsumiya; T Miki; S Suzuki; A Okuyama
Journal:  Immunology       Date:  1998-09       Impact factor: 7.397

8.  RANTES induces tyrosine kinase activity of stably complexed p125FAK and ZAP-70 in human T cells.

Authors:  K B Bacon; M C Szabo; H Yssel; J B Bolen; T J Schall
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

9.  Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells.

Authors:  V N Ngo; H L Tang; J G Cyster
Journal:  J Exp Med       Date:  1998-07-06       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.